AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 152 min read$SERA

Lindgardt Zhenya sold $14K of SERA

Lindgardt Zhenya (Chief Executive Officer) sold 6,990 shares of SERA PROGNOSTICS, INC. (SERA) at $2.01 on 2026-06-11.

Original reporting
SEC EDGAR · Lindgardt Zhenya
Published Jun 15, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SERA
Bearish
medium confidence
Mentioned
$SERA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERABearishLow
01

Why it matters

The newest concrete fact is the CEO’s open-market sale of 6,990 shares at $2.01/share, reported via EDGAR.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not introduce new operating or financial information.

03

What to watch

The filing provides sale size and post-transaction holdings but no context on compensation, tax obligations, or whether other insiders are buying/selling around the same period.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-15; sale executed 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for SERA PROGNOSTICS, INC.

Company-level read

Ticker impact

$SERABearishMedium confidence
Context

SEC Form 4 shows CEO Lindgardt Zhenya sold 6,990 SERA shares in an open-market sale on 2026-06-11.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing discloses a routine Form 4 transaction (open-market sale) with no 10b5-1 plan and no accompanying company-specific news or guidance changes.

Market effects

Sector

No sector-level implications; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

CEO sales can be driven by diversification, taxes, or pre-planned liquidity needs; absence of a 10b5-1 plan does not necessarily imply bearish expectations.

Key entities

  • issuer
    SERA PROGNOSTICS, INC.

    Company whose CEO reported an open-market sale on Form 4.

  • insider
    Lindgardt Zhenya

    CEO and officer/director who sold 6,990 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SERA insider trading history →

Related articles

AUG 19
$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

fool.com2 min
AUG 12
$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

prnewswire.com6 min
AUG 12
$SERAMed

SERA PROGNOSTICS, INC. (SERA): Results of Operations and Financial Condition

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t

SEC EDGAR 8-K4 min